4D Molecular’s wAMD drug is best-in-class, says RBC, sees ‘ideal’ entry point
D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend’s Angiogenesis, Exudation, and ...
Older women face higher risks with new gene therapies for eye diseases, study finds
Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research ...
News Medical4 小时
Research highlights gender and age differences in eye gene therapy responses
Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found.
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock
H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant volatility, with ...